Archive for the ‘HEART & ARTERIES’ Category

How the Heart Can Harden, Biologically

Saturday, November 19th, 2016
With age or injury, the soft tissues of the heart can turn to bone. Is this deadly process reversible?

enrique_simonet__la_autopsia_1890 image

Take heart: researchers are probing how the hard-hearted get that way, and whether they can be turned back. (“La autopsia,” Enrique Simonet / Wikimedia Commons)

In matters of the heart, a lot can go wrong. As we age, high blood pressure can overburden this tenacious muscle, causing stroke or heart failure. Smoking cigarettes may harm your heart and blood vessels, as well as damaging individual blood cells. Or the natural effects of old age can render the heart simply too weak to do its job, manifesting in tiredness, shortness of breath or even death. But the heart can also harden, its soft muscle changing into bone.

“The cardiovascular system is one soft tissue that gets calcified very easily,” said Arjun Deb, a heart researcher at the University of California at Los Angeles, referring to the accumulation of calcium salts in the tissues of the heart. This is a bad development: Calcification in blood vessels can eventually block them up, and in the heart, it can actually block the electric signals that keep the cardiac muscles beating. Normal aging, conditions such as kidney disease or diabetes, or even physical trauma to the chest can trigger heart calcification—but the exact hardening mechanism is still largely unknown.

Now researchers have shed light on this enigmatic process by looking at individual cells to see exactly how the flexible tissues of the heart and blood vessels stiffen, impairing beating and circulation. In a study published yesterday in the journal Stem Cell, Deb and his team sought to find out the cause for deadly heart calcification and how the process could potentially be stopped in its tracks. That would be heartening news. Calcification in the heart and blood vessels is one of the main factors in heart disease, which kills about 610,000 Americans annually, according to the Centers for Disease Control.

Armed with the knowledge that heart injury can often result in calcification, the researchers focused their efforts on fibroblasts, connective tissue cells that play an important role in healing wounds. After an injury, fibrocyte cells in the affected area are activated into fibroblasts, which generate connective tissue for healing. Some of these fibroblasts go awry in soft tissue and become like osteoblasts, the cells that produce bone in the skeletal system.

By genetically tagging the fibroblasts in lab mice and then causing various types of injuries to the animals, the researchers were able to see the nearby fibroblast cells turn into cells resembling osteoblasts. Scientists then took these transformed cells and transplanted them into the skin of healthy mice, where the mutant cells began calcifying the rodents’ skin within a month. When grown in lab dishes, harvested human fibroblast cells did the same thing. The mere presence of these osteoblast-type cells, it seemed, worked to calcify surrounding tissues.

This new understanding helped scientists identify a potential mechanism for preventing a fatal hardening of the heart from ever taking place. While studying these mutating fibroblasts, Deb and his team noticed that the cells started to overproduce a protein called ENPP1 in response to heart injury. When they injected an osteoporosis drug into the mice after injuries that usually resulted in heart calcification, not a single mouse developed heart hardening. The drug seemed to stymie the actions of ENPP1 and thus completely prevent calcification, Deb said.

Unfortunately, it seems that this treatment only works when used before the calcification takes place. This kind of preventative treatment would be impractical in humans, since it would be impossible to know when precisely heart damage takes place, says Dr. Paolo Raggi, academic director of the Mazankowski Alberta Heart Institute in Edmonton, Canada. Raggi, who was not involved in this study, also expressed caution at whether these results in mice would also work in humans.

Nevertheless, he said the researchers did “a fantastic job” at discovering a pathway for how heart calcification occurs. “It’s unbelievable the amount of work they did for one simple question,” Raggi says, noting that the pieces of evidence had been there previously, but that they had not yet been formed into “an elegant story.” “I think there’s definitely potential for future development into this particular field,” he adds.

Deb and his team are already looking ahead to see whether it might be possible not only to prevent, but to reverse a hardened heart. Their next goal is to find out how and why ENPP1 causes calcification after heart injury, in hopes that there might be a way to reverse the hardening. And since this same protein appears to also be involved in calcification in other soft tissues where it shouldn’t occur, Deb hopes that future research on this topic will one day lead to a treatment that can prevent and heal calcification in any part of the body.

“There is promise,” Deb says. In other words: Don’t lose heart.


Henry Sapiecha

Killer Blood Clots — Why They Form and How to Prevent This #1 Killer from Taking Your Life

Monday, July 25th, 2016


Heart disease is the No. 1 killer of men and women in the United States, yet, when you think about this condition you may not automatically equate it with blood clots.

However, most heart attacks (myocardial infarctions) are caused by blood clots that limit or block blood flow to your heart.

If you make it to the emergency room, clot-busting medications may be administered because the faster you can break up the clot, the faster you can restore normal blood flow (i.e, oxygen!) to your body.

Preventing blood clots, then, including “breaking up” any potential clots before they develop, is a key strategy to heart health no matter what your age. One way to do this is to attack clots at their root source: fibrin.

What Are Blood Clots Made of and How Do They Form?

Blood clots are made up primarily of fibrin, an insoluble protein that also makes up scar tissue. Your body produces fibrin in response to bleeding. Specifically, the soluble protein fibrinogen is converted into fibrin at the site of a wound via clotting enzymes called thrombin.[i]

It’s an amazing process that’s absolutely crucial to your health and healing, but it must be properly balanced by the action of plasmin, an enzyme known as your body’s natural blood thinner. Plasmin helps to remove excess or unnecessary accumulated proteins so your blood can flow freely.

If this balance is upset, serious consequences including blood clots and heart attack can result. One study published in the Italian Heart Journal noted:[ii]

When fibrin deposition and removal are properly balanced, the organism is protected from both a catastrophic loss of blood at the site of injury and the inappropriate loss of fluidity within the vascular system.

When these activities are not properly balanced, however, severe bleeding or thromboses [blood clots] can occur. Myocardial infarction [heart attack] is a common and morbid consequence of the latter.”

Atherothrombosis: A Blood Clot Within Your Artery

You’re probably familiar with the term atherosclerosis, which is the buildup of plaque in your arteries. Less widely known, yet the leading cause of death in the Western world,[iii] is atherothrombosis — a blood clot that forms within your artery as a result of atherosclerosis.[iv]

Fibrinogen is one of the most studied risk factors in the development of atherothrombosis.[v] Like atherosclerosis, this condition can progress for years with no symptoms until it finally manifests as a heart attack or sudden death.

Fibrinogen levels may give some insight into your risk of this condition, however, as research shows a significant association between high fibrinogen levels and risk of heart disease, stroke, peripheral arterial disease and cardiovascular death.[vi]

The association is so strong that the risk of cardiovascular events in people with the highest fibrinogen levels was twice that of people with lower levels — and this was true in both healthy people and those already at high risk of heart disease and stroke.[vii] Even slight increases in fibrinogen levels may increase your risk of future heart disease.[viii]

Risks of Hypercoagulation

Hypercoagulation is another condition related to increased fibrin in your blood and, as a result, an increased risk of blood clots and related conditions such as deep vein thrombosis (DVT), pulmonary embolisms (PE), heart attack and stroke. Even kidney failure can occur if a blood clot forms in your kidneys.

Even in cases when excess fibrin does not lead to a blood clot, problems may still occur. Research suggests fibrin deposited in your blood vessels may lead to nutrient deficiencies, lack of oxygen and even chronic fatigue syndrome.[ix][x]

There are many causes of hypercoagulation, including genetic and lifestyle factors. In the latter case, being overweight or obese, smoking, using birth control pills or hormone replacement therapy, long plane or car trips, extended bed rest and pregnancy may all increase your risk.

How to Remove Excess Fibrin From Your Blood

It’s possible to remove excess fibrin in your body. The key is activating your body’s natural fibrin cleanup crew, which is made of proteolytic enzymes, a group of systemic enzymes responsible for breaking down protein molecules. They hit masses of excess fibrin and eat them away — literally!

For instance, after 2 months of taking proteolytic enzymes, healthy study participants had decreases in fibrinogen, factor VII, and factor VIII (other proteins involved in blood clotting) by 9 percent, 14 percent, and 17 percent, respectively.[xi] Those at high risk of heart disease had similar reductions (7 percent, 13 percent, and 19 percent, respectively) after taking the enzymes. Decreases in red blood cell aggregation and blood viscosity have also been demonstrated via proteolytic enzymes.[xii]

Systemic enzymes are naturally produced in your pancreas, but your natural production declines with age; these fibrin busters become largely depleted by age 50, with significant declines beginning as early as your late 20s.

Fortunately, improvement is easy… simply supplement your body’s supply of these vital enzymes for heart health. And, as an added bonus, proteolytic enzymes help fight pain-causing inflammation, cleanse toxins from your blood, fight viruses and fortify your immune system.


Henry Sapiecha

Heart attack, stroke: popular painkillers to carry health warnings after 2016

Saturday, November 21st, 2015

spoonfull of pills image www.newcures.infopulsating heart animation image www.newcures.infoAttention sign image

The warnings will state ‘excessive use can be harmful and increase the risk of heart attack, stroke or liver damage’.

Some of Australia’s most popular painkilling medications will carry warnings from next year that they could put people at risk of heart attack and stroke.

The medications, which contain the active ingredients ibuprofen, diclofenac and naproxen, are freely available at the chemist and supermarket under brand names such as Nurofen, Advil and Voltaren.

Health authorities stopped short of the more radical actions of other countries such as the UK, where diclofenac has been made prescription-only.

Earlier this year, US health authorities warned even a few weeks of using the drugs could increase a person’s risk of a fatal heart attack.

Australia’s Therapeutic Goods Administration (TGA) has been reviewing the safety of the drugs against the back of increasing reports of dangerous cardiovascular complications.

In 2010, Fairfax Media reported that the drugs had been linked to stroke and some experts believed they should be banned or sold only on prescription.

The TGA said its review found the medications were “safe when they were used according to the recommended doses for short durations, as instructed on the label”.

“However, inappropriate use or overuse of these medicines could pose a significant risk of cardiovascular events and, in the case of diclofenac, [liver toxicity],” it said.

The drugs are a type of medicine known as a “non-steroidal anti-inflammatory” medications. Another of this class of drugs, the arthritis drug Vioxx, triggered a $4.85 billion lawsuit amid evidence it doubled the risk of heart attack for patients, causing as many as 140,000 in the US alone.

All forms of ibuprofen, diclofenac and naproxen will now carry a warning that using them at high doses can increase your risk of high blood pressure, heart attack, heart failure and stroke.

The warning will state: “Do not use for more than a few days at a time unless a doctor has told you to. Do not exceed the recommended dose. Excessive use can be harmful and increase the risk of heart attack, stroke or liver damage.”

Most medications will be expected to carry the label by July 2016, although some have been given an extension until January 2017.

The Australian Self Medication Industry supports the changes to the warning labels, however, Alphapharm, which makes non-brand name generic versions of medicines, said while warnings on packets were sufficient for medications sold in pharmacies because of the quality of information provided by pharmacists, product inserts were needed when the drugs were sold at supermarkets to make sure consumers were properly informed.


Henry Sapiecha

Why a weak handshake is bad news for your heart

Thursday, May 14th, 2015

healthy handshake image

Do it for your heart: A healthy handshake.

The strength of your handshake could indicate the chance of a future heart attack, a major study suggests.

Researchers found that the vigour of a person’s grip could predict the risk of heart attacks and strokes – and was a stronger indicator of death than checking systolic blood pressure.

The study in The Lancet, involving almost 140,000 adults in 17 countries, found weak grip strength was linked to shorter survival and a greater risk of having a heart attack or stroke.

Reduced muscular strength, which can be measured by grip strength, has been consistently linked with early death, disability, and illness. But there has been limited research on whether grip strength could be used to indicate heart health.

Grip strength was assessed using a device that measures the force exerted when a subject squeezes an object as hard as possible with their hands.

The findings show that every five-kilo decline in grip strength was associated with a 16 per cent increased risk of death from any cause; a 17 per cent greater risk of cardiovascular death; a 17 per cent higher risk of non-cardiovascular mortality and more modest increases in the risk of having a heart attack (seven per cent) or a stroke (nine per cent).

Overall, grip strength was a stronger predictor of all deaths, including those from heart disease, than systolic blood pressure.

The associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.

Dr Darryl Leong, of McMaster University in Canada, who was the lead author, said: “Grip strength could be an easy and inexpensive test to assess an individual’s risk of death and cardiovascular disease.

“Further research is needed to establish whether efforts to improve muscle strength are likely to reduce an individual’s risk of death and cardiovascular disease.”

The Telegraph, London


Henry Sapiecha

Study Suggests Correlation Between Heart Health and Optimism, so smile more & live longer

Tuesday, April 21st, 2015


grin pink heart bling image

People whose glasses are half-full are reportedly twice as likely to have healthy hearts, according to a new study published in the Health Behavior and Policy Review journal.

“Individuals with the highest levels of optimism have twice the odds of being in ideal cardiovascular health compared to their more pessimistic counterparts,” said Rosalba Hernandez, the lead author of the study and social work professor at the University of Illinois. “This association remains significant, even after adjusting for socio-demographic characteristics and poor mental health.”

The study took stock of more than 5,000 adults’ cardiovascular health and general outlook on life over the course of 11 years, beginning in July 2000. Blood pressure, body mass index, dietary intake, physical activity, tobacco use, cholesterol and blood glucose all factored into an individual subject’s heart health analysis.


Research subjects, all between the ages of 45 and 84 years old, also completed surveys to gauge their self-reported levels of optimism and general states mental health. The study found that those with the highest self-reported levels of optimism were about twice as likely to score strongly in terms of cardiovascular health.

The optimists in the study were found to have better blood sugar and cholesterol levels than their more negative counterparts. Optimism also correlated with higher levels of physical activity, healthier body mass indexes and lower rates of smoking.

The study was conducted by professors from Indiana, Northwestern, Chapman, Harvard and Drexel universities and funded by the National Heart, Lung and Blood Institute and the National Center for Research Resources. Its findings contribute to a growing pool of research suggesting correlation between physical health and mental and emotional wellbeing.

[MORE: 2015 Means First-Time Health Insurance Coverage for Millions of Americans]

Time cites a 2012 Harvard study suggesting a link between “positive psychological well-being” and reduced rates of heart disease and stroke. That particular study acknowledges that psychological well-being is “a broad concept” but ultimately found that, out of a series of psychological indicators, “optimism is most robustly associated with a reduced risk of cardiovascular events.”

A separate 2011 study found that “satisfaction in most life domains was associated with reduced “coronary heart disease risk.”


Henry Sapiecha

Experimental cholesterol drugs could halve heart attack and stroke rates

Wednesday, March 18th, 2015

A new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, preliminary research has found.

A new class of experimental cholesterol drugs may sharply reduce the risk of heart attacks and strokes, initial research has discovered.

by Andrew PollackA new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, researchers reported on Sunday, citing what they described as preliminary evidence.

The drugs, one being developed by Amgen and the other by Sanofi and Regeneron Pharmaceuticals, are already known to sharply reduce so-called bad cholesterol, sometimes to levels lower than those achieved by statins like Lipitor, the mainstay lipid-lowering medicines.

What has not been known, however, is whether the drugs do what patients and doctors really care about: protect against heart attacks, strokes and other cardiovascular problems or “events.”

Big benefits may be possible

The early results suggest that there might be such a benefit, maybe even a big one. In small studies sponsored by the manufacturers, both drugs reduced the rate of such cardiovascular problems by about half.

“To see a reduction in cardiovascular events already is very encouraging that we’re on the right track,” says Jennifer G. Robinson, the lead investigator in the trial of the Sanofi drug.

The studies were published in The New England Journal of Medicine and were presented at the annual meeting of the American College of Cardiology on  Monday in San Diego.

More research required

Researchers caution, however, that the studies were small and intended to assess whether the drugs lower the bad cholesterol and were safe, not whether they stave off heart attacks. That could make the conclusions about heart attack and stroke risk less trustworthy. Judging those effects will require larger trials involving tens of thousands of people; such studies are underway and are expected to be completed by 2017.

“I do not think that either study answers the question definitively of cardiovascular benefit,” says Steven E. Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, referring to the drug makers’ research. He was not involved in either study.

Risk of memory problems

Researchers say long-term safety still must be assessed, especially since these drugs are reducing LDL cholesterol to levels never achieved by medicines before. While the drugs appear to be generally safe, there is evidence that they could cause memory problems.

Still, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.

The drugs, evolocumab from Amgen and alirocumab from Sanofi and Regeneron, inhibit a protein in the body called PCSK9 that helps regulate cholesterol. In the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies. In many cases such big reductions were achieved even though the patients were already taking statins.

Both drugs could win approval from the US Food and Drug Administration by the Northern summer. Analysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins. (However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)

Statins reduce cardiovascular risk and scientists believe it is because they decrease low-density lipoprotein, or LDL, the so-called bad cholesterol. But merely looking at cholesterol levels can be misleading. The drug niacin did not protect against heart attacks and strokes even though it raised so-called good cholesterol and modestly lowered bad cholesterol.

Insurers in particular might demand proof that the PCSK9 drugs stave off heart attacks, strokes, deaths from coronary disease and procedures to open arteries before agreeing to pay for them for many patients. Executives at CVS Health, a leading pharmacy benefits manager, recently said that PCSK9 inhibitors might cost $US7,000 to $US12,000 a year and would strain health care budgets because so many people might use them.

“Managed care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,” they wrote in the Health Affairs blog.

Whether the results from these two small studies will be persuasive enough remains to be seen.

The New York Times


Henry Sapiecha

Craig Lewis: The World’s First Heartless Human

Monday, February 2nd, 2015

Heartless Human

Heart Stop Beating is the story of two visionary Texas Heart Institute doctors, Dr. Billy Cohn and Dr. Bud Frazier. Frustrated by the often short lifespans and mulitple complications of usual heart replacement devices, the two  invented a two centrifugal pump machine. Cohn and Frazier tested the machine by removing the hearts of  several calf’s and replacing them with the device.

After much success it was time for human trials.


The first patient would be Craig Lewis, was 55-year-old dying from amyloidosis, a disease which causes a buildup of abnormal proteins. The proteins clog the organs so much that they stop working. Lewis’ heart was so damaged, he only had 12 hours to live.

So, in March of 2011, the doctors successfully replaced Lewis’ heart with the ‘continuous flow’ device they developed, proving that life was possible without a pulse or a heart beat–essentially without a human heart.

Although Lewis died due to complications from his disease, the heart pumps have yet to wear out like traditional devices, the trade off  is the loss of the familiar and elemental sound of a beating human heart — a small price for a working heart.


Henry Sapiecha

Freedom Driver portable unit allows man with artificial heart to await transplant at home

Wednesday, January 14th, 2015


Heart failure patients awaiting organ transplants normally find themselves anchored to the hospital bed by a washing machine-sized device that keeps blood pumping through their veins. But for Stan Larkin, a patient at the University of Michigan Frankel Cardiovascular Center, a new form of wearable technology is allowing him to keep on the move. The Freedom Driver is a compact, mobile version of the same machine that allows patients like Larkin to go about their normal lives while they wait for a matching donor heart to arrive.

On any given day there are around 3,000 people in the US on the waiting list for a heart transplant, according to the National Heart, Lung and Blood Institute. This organ shortage means that sufferers of advanced heart failure are implanted with devices to aid in survival. In Larkin’s case this involved the removal of his heart and replacing it with an artificial organ, a temporary solution that would keep him alive until another heart became available.


What drives power to Larkin’s artificial heart, and others like it, is a machine that delivers compressed air into the ventricles via two tubes. At first, Larkin was hooked up to the larger, washing machine-sized device. Known as Big Blue, the machine weighs 418 lb (190 kg) and often sees patients remain in hospital for months or even years at a time.

But in June 2014, the Food and Drug Administration approved the aptly named Freedom Driver. Weighing 13 lb (5.9 kg) it performs the same task as Big Blue but is designed to be portable, fitting snugly inside a purpose-made backpack. Patients must meet a certain discharge criteria to make the switch from Big Blue to the Freedom Driver, but once they do they are free to leave the hospital and wait for their new heart at home.


Larkin’s departure from hospital marks the first time that a patient has been switched over to the Freedom Driver at the University of Michigan hospital, and also the first of its patients to take it home in his backpack. He works with therapists to sustain his mobility with the Freedom Driver onboard, is on a number of blood-thinning medications and eats low sodium meals.

“He’s still listed for a heart transplant and we hope to transplant him as soon as an organ is available,” says Jonathan Haft, a cardiac surgeon at the University of Michigan. “In the meantime he can be at home, he can be functional, and continue to rehabilitate himself so he’s in the best possible shape when his opportunity comes.”

You can hear from Larkin in the video below.

Source: University of Michigan


Henry Sapiecha

Stem cell stroke therapy shows promise after first human trial

Thursday, August 14th, 2014

London researchers have revealed that stroke patients in a pilot study all showed improvements after stem cell therapy

imperial-college-stem-cell-stroke skull image

A pilot study undertaken by researchers from Imperial College Healthcare NHS Trust and Imperial College London has shown promise in rapid treatment of serious strokes. The study, the first of its kind published in the UK, treated patients using stem cells from bone marrow.

Imagine a perfectly ordinary beginning to your day, say burned toast, no matching pair of socks and the usual damp commute to work. Except at some point through the usual minutiae you suffer a massive stroke. If you don’t die outright, you may soon afterwards. Even supposing you survive those first days or weeks, the chance of your life resuming its comforting tedium is impossibly remote. You may need assistance for the rest of your shortened life.

According to the Stroke Association, about 152,000 people suffer a stroke in the UK alone each year. However, the five patients treated in the recent Imperial College pilot study all showed improvements. According to doctors, four of those had suffered the most severe kind of stroke, which leaves only four percent of people alive or able to live independently six months after the event. All four of the patients were alive after six months.

A particular set of CD34+ stem cells was used, as they help with the production of blood cells and blood vessels’ lining cells. These same cells have been found to improve the effects of stroke in animals, and they assist in brain tissue and blood growth in the affected areas of the brain. The CD34+ cells were isolated from samples taken from patients’ bone marrow and then infused into the affected area via an artery that leads to the brain, using keyhole surgery.

The innovative stem cell treatment differs from others in one important way: patients are treated within seven days of their stroke, rather than six months hence. The stroke sufferers all recorded improvements in terms of clinical measures of disability, despite four of the five having suffered the most severe kind of stroke.

It’s still early days for the research, and much more will need to be done to expand clinical trials, but eventually it is hoped that a drug may be developed that can be administered to stroke sufferers as soon as they are admitted to hospital. This could ameliorate longer term effects and allow for speedier recovery and a faster entry into therapy.

A paper detailing the research was published in journal Stem Cells Translational Medicine.

Source: Imperial College London

Henry Sapiecha


Monday, July 29th, 2013

Just an introduction into the world of nuclear medicine in Australia from the recent experience of your truly Henry Sapiecha.

I was in for a checkup for heart health in the Fraser Coast Qld under the care of a nuclear medicine & heart specialist Dr Steven Mego. Highly recommended by me.

The experience was interesting and professional under his care with some pics attached herein during my tests

Yes, I am not heartless as they did actually find a heart.

Henry Sapiecha

Henry Sapiecha heart scan stuff June 2013 (2)

Henry Sapiecha has he got test a heart image www.sapiecha (2)

Henry Sapiecha has he got test a heart image www.sapiecha (1)

Henry Sapiecha undergoing heart test MB 13th June 2013.www.newcures (1)

Henry Sapiecha undergoing heart test MB 13th June 2013.www.newcures (4)

Henry Sapiecha undergoing heart test MB 13th June 2013.www.newcures (3)

The male nurse above loves his job by the look on his face

He must enjoy the needlework:Perhaps he should have been a…….??

Dr Stephen Mego has a practice in Brisbane Queensland and his web site below.

Dr Stephen Mego, Royal Brisbane and Women’s Hospital, Australia
Dr David Seaton     Dr Myles Webb     Dr Stephen Mego

Ground Floor, Private Practice Clinic
The Prince Charles Hospital
627 Rode Road, Chermside, QLD, 4032
Postal Address :  P.O.Box 2491,  Fortitude Valley BC QLD 4006
Phone :  07 3139 4010
Fax :  07 3139 4577
Dr Stephen Mego  MBBS(Hons) FRACP
Nuclear Physician, Paediatrician
Stephen graduated in Medicine from the University of Queensland in 1986 with first class honours and a university medal. He completed his residency at the Royal Brisbane Hospital and then trained in general paediatrics at the Royal Children’s Hospital, Herston, Queensland. He became a fellow of the College of Physicians in 1995 and worked as a consultant Paediatrician for 8 years with the Redcliffe-Caboolture Health Service.Subsequently he underwent sub-speciality training in Nuclear Medicine at the Royal Brisbane Hospital and completed this Nuclear Medicine training at the Princess Alexandra Hospital in 2006.  He presently works as a VMO in Nuclear Medicine at the Princess Alexandra Hospital and the Wesley Hospital as well as working in the private partnership at Queensland Nuclear Imaging.His professional interests include Nuclear Cardiology, Paediatric Nuclear medicine and Positron Emission Tomography.